US20040242494A1 - Caspase inhibitors and uses thereof - Google Patents

Caspase inhibitors and uses thereof Download PDF

Info

Publication number
US20040242494A1
US20040242494A1 US10/855,699 US85569904A US2004242494A1 US 20040242494 A1 US20040242494 A1 US 20040242494A1 US 85569904 A US85569904 A US 85569904A US 2004242494 A1 US2004242494 A1 US 2004242494A1
Authority
US
United States
Prior art keywords
aliphatic
aryl
heteroaryl
heterocyclyl
cycloaliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/855,699
Other languages
English (en)
Inventor
Guy Brenchley
Jean-Damien Charrier
Steven Durrant
Ronald Knegtel
Michael Mortimore
John Studley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to US10/855,699 priority Critical patent/US20040242494A1/en
Assigned to VERTEX PHARMACEUTICALS INCORPORATED reassignment VERTEX PHARMACEUTICALS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHARRIER, JEAN-DAMIEN, STUDLEY, JOHN R., DURRANT, STEVEN, MORTIMORE, MICHAEL, BRENCHLEY, GUY, KNEGTEL, RONALD
Publication of US20040242494A1 publication Critical patent/US20040242494A1/en
Priority to US12/140,497 priority patent/US7960415B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit caspases that mediate cell apoptosis and inflammation.
  • the invention also relates to processes for preparing these compounds.
  • the invention further relates to methods of using the compounds and pharmaceutical compositions of this invention to treat diseases where caspase activity is implicated.
  • Apoptosis or programmed cell death, is a principal mechanism by which organisms eliminate unwanted cells.
  • Caspases are a family of cysteine protease enzymes that are key mediators in the signaling pathways for apoptosis and cell disassembly (Thornberry, Chem. Biol., 1998, 5, R97-R103). These signaling pathways vary depending on cell type and stimulus, but all apoptosis pathways appear to converge at a common effector pathway leading to proteolysis of key proteins. Caspases are involved in both the effector phase of the signaling pathway and further upstream at its initiation. The upstream caspases involved in initiation events become activated and in turn activate other caspases that are involved in the later phases of apoptosis.
  • Caspase-1 the first identified caspase, is also known as interleukin converting enzyme or “ICE.” Caspase-1 converts precursor interleukin-1 ⁇ (“pIL-1 ⁇ ”) to the pro-inflammatory active form by specific cleavage of pIL-1 ⁇ between Asp-116 and Ala-117. Besides caspase-1 there are also eleven other known human caspases, all of which cleave specifically at aspartyl residues. They are also observed to have stringent requirements for at least four amino acid residues on the N-terminal side of the cleavage site.
  • the caspases have been classified into three groups depending on the amino acid sequence that is preferred or primarily recognized.
  • the group of caspases which includes caspases 1, 4, 5 and 13, have been shown to prefer hydrophobic aromatic amino acids at position 4 on the N-terminal side of the cleavage site.
  • Another group which includes caspases 2, 3 and 7, recognize aspartyl residues at both positions 1 and 4 on the N-terminal side of the cleavage site, and preferably a sequence of Asp-Glu-X-Asp.
  • caspases have also been grouped according to their perceived function.
  • the first subfamily consists of caspases-1 (ICE), 4, 5 and 13. These caspases have been shown to be involved in pro-inflammatory cytokine processing and therefore play an important role in inflammation.
  • Caspase-1 the most studied enzyme of this class, activates the IL-1 ⁇ precursor by proteolytic cleavage. This enzyme therefore plays a key role in the inflammatory response.
  • Caspase-1 is also involved in the processing of interferon- ⁇ inducing factor (IGIF, also known as IL-18) which stimulates the production of interferon gamma, a key immunoregulator that modulates antigen presentation, T-cell activation and cell adhesion.
  • IGIF interferon- ⁇ inducing factor
  • caspases make up the second and third subfamilies. These enzymes are of central importance in the intracellular signaling pathways leading to apoptosis.
  • One subfamily consists of the enzymes involved in initiating events in the apoptotic pathway, including transduction of signals from the plasma membrane. Members of this subfamily include caspases-2, 8, 9 and 10.
  • the other subfamily consisting of the effector capsases 3, 6 and 7, are involved in the final downstream cleavage events that result in the systematic breakdown and death of the cell by apoptosis.
  • Caspases involved in the upstream signal transduction activate the downstream caspases, which then disable DNA repair mechanisms, fragment DNA, dismantle the cell cytoskeleton and finally fragment the cell.
  • R is an acyloxymethylketone —COCH 2 OCOR′.
  • R′ is exemplified by an optionally substituted phenyl such as 2,6-dichlorobenzoyloxy and where R is COCH 2 X where X is a leaving group such as F or Cl.
  • caspase inhibitors to treat a variety of mammalian disease states associated with an increase in cellular apoptosis has been demonstrated using peptidic caspase inhibitors.
  • caspase inhibitors have been shown to reduce infarct size and inhibit cardiomyocyte apoptosis after myocardial infarction, to reduce lesion volume and neurological deficit resulting from stroke, to reduce post-traumatic apoptosis and neurological deficit in traumatic brain injury, to be effective in treating fulminant liver destruction, and to improved survival after endotoxic shock.
  • peptidic inhibitors described above are very potent against some of the caspase enzymes. However, this potency has not always been reflected in cellular models of apoptosis.
  • peptide inhibitors are typically characterized by undesirable pharmacological properties such as poor oral absorption, poor stability and rapid metabolism. Plattner and Norbeck, in Drug Discovery Technologies , Clark and Moos, Eds. (Ellis Horwood, Chichester, England, 1990).
  • peptidomimetic inhibitors Recognizing the need to improve the pharmacological properties of the peptidic caspase inhibitors, peptidomimetic inhibitors have been reported. Amongst these, inhibitors where the P3 amino acid has been replaced by derivatives of 3-aminopyridin-2-ones and 5-aminopyrimidin-4-ones have been reported (U.S. Pat. No. 5,756,466 (Bemis et al.); PCT Publication No. WO 95/35308 (Bemis et al.); Dolle et al. J. Med. Chem. 39, 2438, (1996); Golec et al. Bioorg. Med. Chem. Lett. 7, 2181, (1997); Semple et al, Biorg. Med. Chem. Lett. 7, 1337, (1997)).
  • R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein.
  • the present invention also provides pharmaceutical compositions comprising a compound of formula I and methods using such compounds and compositions for treating caspase-mediated diseases.
  • the present invention also provides processes for preparing the compounds of formula I.
  • R 1 is R 6 C(O)—, HC(O)—, R 6 SO 2 —, R 6 OC(O)—, (R 6 ) 2 NC(O)—, (R 6 ) (H)NC(O)—, R 6 C(O)C(O)—, R 6 —, (R 6 ) 2 NC(O)C(O)—, (R 6 ) (H)NC(O)C(O)—, or R 6 OC(O)C(O)—;
  • R 2 is hydrogen, —CF 3 , halo, —OR 7 , —NO 2 , —OCF 3 , —CN, or R 8 ;
  • R 3 is hydrogen or (C1-C4)-aliphatic-;
  • R 4 is —COOH or —COOR 8 ;
  • R 5 is —CH 2 F or —CH 2 O-2,3,5,6-tetrafluorophenyl
  • R 6 is (C1-C12)-aliphatic-(C3-C10)-cycloaliphatic-, (C6-C10)-aryl-, (C3-C10)-heterocyclyl-, (C5-C10)-heteroaryl-, (C3-C10)-cycloaliphatic-(C1-C12)-aliphatic-, (C6-C10)-aryl-(C1-C12)-aliphatic-, (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-, (C5-C10)-heteroaryl(C1-C12)-aliphatic-, or two R 6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein the ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or
  • R is halogen, —OR 7 , —OC(O)N(R 7 ) 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 7 , oxo, thioxo, ⁇ NR 7 , ⁇ N(OR 7 ), 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 7 ) 2 , —SR 7 , —SOR 7 , —SO 2 R 7 , —SO 2 N(R 7 ) 2 , —SO 3 R 7 , —C(O)R 7 , —C(O)C(O)R 7 , —C(O)C(O)OR 7 , —C(O)C(O)N(R 7 ) 2 , —C(O)CH 2 C(O)R 7 , —C(S)R 7 , —C(S)OR 7 , —C(O)OR 7 , —C
  • two R 7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, N(R), O, S,SO, or SO 2 , wherein the ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J 2 ; or
  • each R 7 is independently selected from:
  • R 7 has up to 3 substituents selected independently from J 2 ;
  • J 2 is halogen, —OR 7 , —OC(O)N(R 7 ) 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 7 , oxo, thioxo, ⁇ NR 7 , ⁇ NOR 7 , 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 7 ) 2 , —SR 7 , —SOR 7 , —SO 2 R 7 , —SO 2 N(R 7 ) 2 , —SO 3 R 7 , —C(O)R 7 , —C(O)C(O)R 7 , —C(O)C(O)OR 7 , —C(O)C(O)N(R 7 ) 2 , —C(O)CH 2 C(O)R 7 , —C(S)R 7 , —C(S)OR 7 , —C(O)OR 7 , —C(
  • R 8 is (C1-C12)-aliphatic-(C3-C10)-cycloaliphatic-, (C6-C10)-aryl-, (C3-C10)-heterocyclyl-, (C5-C10)-heteroaryl-, (C3-C10)-cycloaliphatic-(C1-C12)-aliphatic-, (C6-C10)-aryl-(C1-C12)-aliphatic-, (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-, or (C5-C10)-heteroaryl(C1-C12)-aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from O, N, N(R), S, SO, and SO 2 ; and wherein
  • R 8 is optionally substituted with up to 6 substituents independently selected from R.
  • the present invention also provides a compound of formula I:
  • R 1 is R 6 C(O)—, R 6 SO 2 —, R 6 OC(O)—, (R 6 ) 2 NC(O)—, R 6 C(O)C(O)—, R 6 —, (R 6 ) 2 NC(O)C(O)—, or R 6 OC(O)C(O)—;
  • R 2 is hydrogen, —CF 3 , halo, —OR 7 , —NO 2 , —OCF 3 , —CN, or R 8 ;
  • R 3 is hydrogen or (C1-C4)-aliphatic-;
  • R 4 is —COOH or —COOR 8 ;
  • R 5 is —CH 2 F or —CH 2 O-2,3,5,6-tetrafluorophenyl
  • R 6 is (C1-C12)-aliphatic-(C3-C10)-cycloaliphatic-, (C6-C10)-aryl-, (C3-C10)-heterocyclyl-, (C5-C10)-heteroaryl-, (C3-C10)-cycloaliphatic-(C1-C12)-aliphatic-, (C6-C10)-aryl-(C1-C12)-aliphatic-, (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-, (C5-C10)-heteroaryl(C1-C12)-aliphatic-, or two R 6 groups bound to the same atom form together with that atom a 3- to 10-membered aromatic or nonaromatic ring; wherein the ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or
  • R is halogen, —OR 7 , —OC(O)N(R 7 ) 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 7 , oxo, thioxo, 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 7 ) 2 , —SR 7 , —SOR 7 1 , —SO 2 R 7 , —SO 2 N(R 7 ) 2 , —SO 3 R 7 , —C(O)R 7 , —C(O)C(O)R 7 , —C(O)CH 2 C(O)R 7 , —C(S)R 7 , —C(O)OR 7 , —OC(O)R 7 , —C(O)N(R 7 ) 2 , —OC(O)N(R 7 ) 2 , —C(S)N(R 7 ) 2 , —C(
  • two R 7 groups together with the atoms to which they are bound form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N(H), N(R), O, S, SO, or SO 2 , wherein the ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, and wherein any ring has up to 3 substituents selected independently from J 2 ; or
  • each R 7 is independently selected from:
  • R 7 has up to 3 substituents selected independently from J 2 ;
  • J 2 is halogen, —OR 7 , —OC(O)N(R 7 ) 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 7 , oxo, thioxo, 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 7 ) 2 , —SR 7 —SOR 7 , —SO 2 R 7 , —SO 2 N(R 7 ) 2 , —SO 3 R 7 , —C(O)R 7 , —C(O)C(O)R 7 , —C(O)CH 2 C(O)R 7 , —C(S)R 7 , —C(O)OR 7 , —OC(O)R 7 , —C(O)N(R 7 ) 2 , —OC(O)N(R 7 ) 2 , —C(S)N(R 7) 2 , —(CH
  • R 8 is (C1-C12)-aliphatic-(C3-C10)-cycloaliphatic-, (C6-C10)-aryl-, (C3-C10)-heterocyclyl-, (C5-C10)-heteroaryl-, (C3-C10)-cycloaliphatic-(C1-C12)-aliphatic-, (C6-C10)-aryl-(C1-C12)-aliphatic-, (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-, or (C5-C10)-heteroaryl(C1-C12)-aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from O, N(H), N(R), S, SO, and SO 2 .
  • R 1 is R 6 C(O)—, R 6 SO 2 —, or R 6 —.
  • R 1 is R 6 C(O)—.
  • R 1 is R 6 SO 2 —.
  • R 1 is R 6 —.
  • R 1 is (R 6 ) 2 NC(O)—or (R 6 )OC(O)—.
  • R 1 is (R 6 ) 2 NC(O)—.
  • R 1 is (R 6 )(H)NC(O)—.
  • R 1 is (R 6 )OC(O)—.
  • each R 6 is independently (C1-C4)-aliphatic-, (C3-C10)-cycloaliphatic, (C3-C10)-heterocyclyl, (C5-C10)-heteroaryl, (C6-C10)-aryl-, or (C6-C10)-aryl-(C1-C12)-(it being understood that optionally up to 3 aliphatic carbon atoms may be replaced by a group selected from O, N, N(R), S, SO, and SO 2 ; and wherein R 6 is optionally substituted with up to 6 substituents independently selected from R or R 6 is substituted as disclosed in any of the embodiments herein).
  • each R 6 is independently H, (C1-C4)-aliphatic- or (C6-C10)-aryl- or each R 6 together with the N-atom is a (C3-C7)-cycloaliphatic.
  • each R 6 is independently (C1-C4)-aliphatic-, (C5-C10)-heteroaryl-, or (C6-C10)-aryl-, wherein the heteroaryl or aryl is optionally substituted or wherein each R 6 together with the N-atom is a (C3-C7)-cycloaliphatic group.
  • each R 6 is independently (C1-C4)-aliphatic- or (C6-C10)-aryl-, wherein the aryl is optionally substituted or wherein each R 6 together with the N-atom is a (C3-C7)-cycloaliphatic.
  • each R 6 is independently (C1-C4)-aliphatic-, (C3-C7)-cycloaliphatic, (C6-C10)-aryl-, (C5-C10)-heteroaryl, wherein the heteroaryl and aryl are independently and optionally substituted, or each R 6 together with the N-atom is a (C3-C7)-cycloaliphatic.
  • R 2 is hydrogen, C1-, C2-, C3-, or C4-alkyl-, —CF 3 , —C1, —OR 7 , —NO 2 , —OCF 3 , or —CN. More preferably, R 2 is hydrogen, C1-alkyl-, C2-alkyl-, or CF 3 . More preferably, R 2 is hydrogen or CF 3 .
  • R 3 is ethyl
  • R 5 is —CH 2 O-2,3,5,6-tetrafluorophenyl.
  • R 5 is —CH 2 F.
  • R 8 is (C1-C12)-alkyl. More preferably, R 8 is (C1-C4)-alkyl.
  • each R and J 2 are independently halogen, —OR 7 , —OC(O)N(R 7 ) 2 , —NO 2 , —CN, —CF 3 , —OCF 3 , —R 7 , oxo, 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 7 ) 2 , —C(O)R 7 , —C(O)C(O)R 7 , —C(O)OR 7 , —OC(O)R 7 , —C(O)N(R 7 ) 2 , or —OC(O)N(R 7 ) 2 .
  • the carbon atom designations may have the indicated integer and any intervening integer.
  • the number of carbon atoms in a (C1-C4)-alkyl group is 1, 2, 3, or 4. It should be understood that these designation refer to the total number of atoms in the appropriate group.
  • the total number of carbon atoms and heteroatoms is 3 (as in aziridine), 4, 5, 6 (as in morpholine), 7, 8, 9, or 10.
  • an aliphatic group includes straight-chained and branched groups having the specified number of atoms. If the number of atoms is unspecified, the aliphatic group has from 1 to 12 carbon atoms. As would be understood, alkenyl and/or alkynyl aliphatic groups have a minimum of 2 carbon atoms. Preferred aliphatic groups are alkyl groups (preferably having from 1 to 6 atoms).
  • preferred aliphatic groups of this invention are alkyl groups and have 1, 2, 3, 4, 5, or 6 carbon atoms. More preferred alkyl groups have 1, 2, 3, or 4 carbon atoms.
  • Preferred alkenyl and alkynyl groups of this invention have 2, 3, 4, 5, or, 6 carbon atoms and more preferably, from 2, 3, or 4 carbon atoms.
  • Cycloalkyl and cycloalkenyl groups have between 3 and 10 carbon atoms and are monocyclic or bicyclic, including linearly fused, bridged, or spirocyclic.
  • a cycloaliphatic group is, preferably, a cycloalkyl or a cylcoalkenyl. More preferred cycloaliphatic groups are 3-, 4-, 5-, 6-, or 7-membered rings that are, more preferably, cycloalkyl rings.
  • aromatic group or “aryl” refers to a 6-10-membered ring system that contains at least one aromatic ring.
  • aromatic rings include phenyl and naphthyl.
  • heteroaryl refers to ring system having 5-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R), O, S, SO, and SO 2 ., wherein at least one ring is heteroaromatic (e.g., pyridyl, thiophene, or thiazole).
  • Preferred heteroaryl groups are 5- or 6-membered rings having 1 or 2 heteroatoms. In certain embodiments of this invention, more preferred heteroaryl groups are those that have contain a “ ⁇ N” group.
  • heteroaryl rings examples include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-
  • heterocycle refers to ring system having 3-10 members and 1, 2, or 3 heteroatoms independently selected from N, N(R), O, S, SO, and SO 2 , wherein no ring is aromatic (e.g., piperidine and morpholine).
  • Preferred heterocyclyl groups are 5- or 6-membered rings having 1 or 2 heteroatoms.
  • heterocyclic rings include 3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-pyrazol
  • any of these cycloaliphatic, heterocyclyl, and heteroaryl groups are optionally fused with a 5- or 6-membered aryl or heteroaryl ring.
  • each of any aliphatic, aryl, cycloaliphatic, heteroaryl, and heterocyclyl may contain appropriate substituents (preferably up to 5, more preferable up to 3, and even more preferably, 0 or 1) independently selected from, for example, carbonyl and R.
  • Preferred substituents are halogen, —OR 7 , —NO 2 , —CF 3 , —OCF 3 , —R 7 , oxo, —OR 7 , —O-benzyl, —O-phenyl, 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R 7 ) 2 , —C(O)R 7 , —COOR 7 or —CON(R 7 ) 2 , wherein R 7 is defined herein (and is preferably H, (C1-C6)-alkyl, or (C2-C6)-alkenyl and alkynyl), with (C1-C6)-alkyl being most preferred). It should be understood that this definition would include a perfluorinated alkyl group.
  • R is a substituent on a nitrogen atom
  • preferred R groups are selected from the group consisting of —R 7 , —SOR 7 , —SO 2 R 7 , —SO 2 N(R 7 ) 2 , —SO 3 R 7 , —C(O)R 7 , —C(O)C(O)R 7 , —C(O)C(O)OR 7 , —C(O)C(O)N(R 7 ) 2 , —C(O)CH 2 C(O)R 7 , —C(S)R 7 , —C(S)OR 7 , —C(O)OR 7 , —C(O)OR 7 , —C(O)N(R 7 ) 2 , —C(S)N(R 7 ) 2 , —(CH 2 ) 0-2 NHC(O)R 7 , —N(R 7 )N(R 7 )COR 7 , —N(R 7
  • the compounds of the present invention are broad caspase inhibitors and have an improved ability over reported compounds to inhibit apoptosis (see Examples 42 and 43).
  • this invention provides a compound of formula Ia or Ib
  • R 1 , R 2 , R 3 , and R 4 are as defined in any of the embodiments herein.
  • the compound of formula I of present invention provides a compound of formula II, selected from Table 1 below: TABLE 1 Compounds of the invention.
  • R 1 R 2 R 3 R 5 1 Me(C ⁇ O)— H Et CH 2 O— 2,3,5,6-tetrafluorophenyl 2 Et(C ⁇ O)— H Et CH 2 O— 2,3,5,6-tetrafluorophenyl 3 n-Pr(C ⁇ O)— H Et CH 2 O— 2,3,5,6-tetrafluorophenyl 4 c-Pr(C ⁇ O)— H Et CH 2 O— 2,3,5,6-tetrafluorophenyl 5 i-Pr(C ⁇ O)— H Et CH 2 O— 2,3,5,6-tetrafluorophenyl 6 MeOCH 2 (C ⁇ O)— H Et CH 2 O— 2,3,5,6-tetrafluorophenyl 7 2-Furyl(C ⁇ O)— H Et CH 2 O— 2,
  • the present invention provides a pharmaceutical composition comprising:
  • Typical protecting groups may be used in the methods of this invention (see, e.g., T. W. Greene & P. G. M Wutz, “Protective Groups in Organic Synthesis”, 3 rd Edition, John Wiley & Sons, Inc. (1999) and the earlier editions of this book).
  • Typical functional groups that must be protected are amines. Any amines and other functional groups may be protected according to methods known in the art. Compounds, including amines, may be used with or without isolation from the reaction mixtures.
  • EDC is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
  • HOBt 1-hydroxybenzotriazole
  • THF is tetrahydrofuran
  • TFA is trifluoroacetic acid
  • DCM is dichloromethane
  • DMAP 4-dimethylaminopyridine.
  • Acid 1 is coupled to amino alcohol 2.
  • the coupling is depicted using EDC/DMAP/HOBt/THF, however, other suitable conditions may also be used.
  • an amino ketone may be used, in place of the amino alcohol, thus avoiding the subsequent oxidation step.
  • amino alcohol 2 may be obtained according to the method of Revesz et al., Tetrahedron Lett. 1994, 35, 9693.
  • amino alcohol 2 may be obtained by methods analogous to those of Semple et al., Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1337 (Scheme II).
  • R 4 in 3 is preferably an ester that is hydrolyzed in the final step of the scheme. If that ester is a t-butyl ester (i.e., if R 4 is CO 2 tBu), treatment with trifluoroacetic acid will give the acid.
  • the ester is preferably a t-butyl ester when the other substituents in I are compatible with acidic conditions.
  • R 4 in product I is an ester
  • the desired ester may be prepared by esterifying the corresponding acid or by having the desired ester group already present in compound 2.
  • KF potassium fluoride
  • DMF N,N-dimethylformamide
  • ArOH 2,3,5,6-tetrafluorophenol
  • THF tetahydrofuran
  • MeOH methanol.
  • bromoketone 4 R 4 ⁇ CO 2 tBu
  • the ketone is then reduced with, for example, sodium borohydride to give the alcohol 6, which is hydrogenated by using, for example, palladium on carbon as catalyst to give the amino alcohol 2 (R 4 ⁇ CO 2 tBu, R 5 ⁇ CH 2 O-2,3,5,6-tetrafluorophenyl).
  • R 1 is required to be RC ⁇ O (an amide) then an appropriately substituted acid chloride may be used. If R 1 is required to be RS( ⁇ O) 2 (sulphonamide) then an appropriately substituted sulfonyl chloride may be used. If R 1 is RO(C ⁇ O) (carbamate) then an appropriately substituted chloroformate may be used. If R 1 is RN(C ⁇ O) (urea) then an appropriately substituted carbamoyl chloride or isocyanate may be used. The other R 1 groups may be prepared accordingly. Acid 1 is then prepared by deprotection of the ester by, for example, using trifluoroacetic acid. The acid is then coupled to amino alcohol 2 (Scheme 1).
  • Another embodiment of this invention provides a process for preparing a compound of formula I:
  • R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in any of the embodiments herein, comprising:
  • R 9 is —NO 2 , —C(O)OR 10 , R 6 C(O)N(H)—, R 6 SO 2 N(H)—, R 6 OC(O)N(H)—, (R 6 ) 2 NC(O)N(H)—, R 6 C(O)C(O)N(H)—, R 6 N(H)—, (R 6 ) 2 NC(O)C(O)N(H)—, or R 6 OC(O)(O)N(H)—;
  • R 10 is independently hydrogen, (C1-C12)-aliphatic-(C3-C10)-cycloaliphatic-, (C6-C10)-aryl-, (C3-C10)-heterocyclyl-, (C5-C10)-heteroaryl-, (C3-C10)-cycloaliphatic-(C1-C12)-aliphatic-, (C6-C10)-aryl-(C1-C12)-aliphatic-, (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-, (C5-C10)-heteroaryl(C 1 -C12)-aliphatic-, wherein up to 3 aliphatic carbon atoms may be replaced with a group selected from O, N(H), N(R), S, SO, and SO 2 ; and wherein R 10 is optionally substituted with up to 6 substituents independently selected from R; and
  • R, R 2 , R 3 and R 6 are as defined in any of the embodiments of formula (I) herein;
  • Y is either a carbonyl group or an OH group
  • R 4 and R 5 are as defined in any of the embodiments of formula (I) herein;
  • the process further comprises (b) oxidizing the OH group to provide the compound of formula (I);
  • the process comprises the further step of converting the —NO 2 , —C(O)OR 10 , or —CN into R 6 C(O)N(H)—, R 6 SO 2 N (H)—, R 6 OC(O)N(H)—, (R 6 ) 2 NC(O)N(H)—, R 6 C(O)C(O)N(H)—, R 6 N(H)—, (R 6 ) 2 NC(O)C(O)N(H)—, or R 6 OC(O)C(O)N(H)—.
  • the coupling conditions may be any known to skilled practitioners for forming peptidyl bonds. Preferred coupling conditions are EDC/DMAP/HOBt. A preferred solvent in the above embodiment is THF.
  • R 2 , R 3 , and R 9 are as defined herein;
  • [0126] is prepared by a process comprising:
  • R, R 2 , R 3 , and R 9 are as defined herein;
  • the deprotecting conditions will depend on the specific protecting group (i.e., R 10 ). For example, if R 10 is t-butyl, then preferred deprotecting conditions would include acid hydrolysis. A preferred acid is TFA. A preferred solvent is DCM. More preferably the solvent and the hydrolyzing conditions comprise TFA and DCM. If R 10 is methyl or ethyl, then preferred deprotecting conditions would be basic (e.g., aqueous NaOH). If R 10 is benzyl, then the benzyl group could be removed by hydrogenolysis.
  • R 2 , R 3 , R 9 , and R 10 are as defined herein;
  • [0133] is prepared by a process comprising:
  • R 3 and R 10 are as defined herein;
  • X is —I, —Br, —Cl, —OH, an alkylsulfonate, or an aryl sulfonate.
  • X is —OH
  • an appropriate leaving group may be generated in situ (e.g., as in the Mitsunobu reaction).
  • Preferred sulfonates include —O-trifluoromethanesulfonate, —O-methanesulfonate, —O-benzenesulfonate, —O-p-toluenesulfonate, —O-m-nitrobenzenesulfonate, and —O-p-nitrobenzenesulfonate.
  • Suitable leaving groups useful in the methods of this invention are well known in the art. See, e.g., “March's Advanced Organic Chemistry”, 5 th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York (2001).
  • Any solvent that is compatible with the generation of anions may be used.
  • Preferred solvents include DMF, toluene, and THF.
  • Suitable bases include any that may remove a proton from the hydroxy group in (V).
  • Such bases include BuLi, LDA, LHMDS, and NaH.
  • the base is NaH.
  • Another embodiment of this invention provides a process for preparing a compound of formula (VIII):
  • R 2 is —CF 3 , —Cl, —OR 7 , —NO 2 , —OCF 3 , —CN, or R 8 ;
  • R 3 , R 8 , R 9 , and R 10 are as defined herein;
  • R 3 and R 10 are as defined herein;
  • X is a suitable leaving group
  • X is —I, —Br, —Cl, —OH, an alkylsulfonate, or an aryl sulfonate.
  • X is —OH
  • an appropriate leaving group may be generated in situ (e.g., as in the Mitsunobu reaction).
  • Preferred sulfonates include —O-trifluoromethanesulfonate, —O-methanesulfonate, —O-benzenesulfonate, —O-p-toluenesulfonate, —O-m-nitrobenzenesulfonate, and —O-p-nitrobenzenesulfonate.
  • Any solvent is compatible with the generation of anions may be used.
  • Such solvents include DMF, toluene, and THF.
  • the solvent is THF.
  • Suitable bases include any that may remove a proton from the hydroxy group in (V).
  • Such bases include BuLi, LDA, LHMDS, and NaH.
  • the base is NaH.
  • Another embodiment of this invention provides a process for preparing a compound of formula (I):
  • R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in any of the embodiments herein, comprising:
  • R 9 is —NO 2 , —C(O)OR 10 , —CN, R 6 C(O)N(H)—, R 6 SO 2 N(H)—, R 6 OC(O)N(H)—, (R 6 ) 2 NC(O)N(H)—, R 6 C(O)C(O)N(H)—, R 6 N(H)—, (R 6 ) 2 NC(O)C(O)N(H)—, or R 6 OC(O)C(O)N(H)—; and
  • R 2 , R 3 and R 6 are as defined herein;
  • Y is either a carbonyl group or an OH group
  • R 4 and R 5 are as defined herein;
  • the process further comprises (b) oxidizing the OH group to provide the compound of formula (I);
  • the process comprises the further step of converting the 'NO 2 , —C(O)OR 10 , or —CN into R 6 (O)N(H)—, R 6 SO 2 N(H)—, R 6 OC(O)N(H)—, (R 6 ) 2 NC(O)N(H)—, R 6 C(O)C(O)N(H)—, R 6 N(H)—, (R 6 ) 2 NC(O)C(O)N(H)—, or R 6 OC(O)C(O)N(H)—.
  • the compounds of this invention can be assayed for their ability to inhibit the release of IL-1 ⁇ , caspase activity, or apoptosis directly. Assays for each of the activities are known in the art. Selected assays are described below.
  • salts of the compounds of this invention are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamo
  • Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such
  • compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial g
  • compositions of this invention are formulated for pharmaceutical administration to a mammal, preferably a human being.
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions are particularly useful in therapeutic applications relating to an IL-1 mediated disease, an apoptosis mediated disease, an inflammatory disease, an autoimmune disease, a destructive bone disorder, a proliferative disorder, an infectious disease, a degenerative disease, a disease associated with cell death, or various forms of liver disease.
  • Such diseases include those related to rheumatology and autoimmunity, such as rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, myasthenia gravis, autoimmune neutropenia, autoimmune hemolytic anemia, thrombocytopenia, juvenile rheumatoid arthritis, gout, Behcet's syndrome, Still's syndrome, macrophage activation syndrome, and sarcoidosis; auto-inflammatory syndromes, such as cryopyrin-associated Periodic Syndromes, (including Muckle-Wells syndrome, familial cold urticaria, chronic infantile neurological cutaneous and articular syndrome (a.k.a.
  • pulmonary fibrosis atopic dermatitis, scarring, alopecia, acne vulgaris, and pemphigus
  • dermatology such as psoriasis, atopic dermatitis, scarring, alopecia, acne vulgaris, and pemphigus
  • respiratory such as asthma, adult respiratory distress syndrome, cystic fibrosis, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis
  • internal medicine such as inflammatory peritonitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, autoimmune gastritis, H.pylori -associated gastric and duodenal ulcer disease, diabetes, pancreatitis, glomerulonephritis, chronic active hepatitis, excess dietary alcohol intake disease, renal disease, polycystic kidney disease, burns, organ apoptosis
  • GVHD host disease
  • organ transplant rejection organ transplant rejection
  • oncology such as leukemias and related disorders, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, and multiple myeloma
  • cardiovascular such as chronic heart disease, acute heart disease, myocardial infarction, myocardial ischemia, congestive heart failure, atherosclerosis, coronary artery bypass graft (CABG), and acute coronary syndrome
  • CABG coronary artery bypass graft
  • the central and peripheral nervous systems such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, cerebral ischemia, epilepsy, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis, HIV-related encephalitis, traumatic brain injury, spinal cord injury, neurological damage due to stroke, diabetic
  • the compounds and compositions are also useful in treating complications associated with coronary artery bypass grafts.
  • the amount of compound present in the above-described compositions should be sufficient to cause a detectable decrease in the severity of the disease or in caspase activity and/or cell apoptosis, as measured by any of the assays known in the art.
  • compositions of this invention may further comprise another therapeutic agent.
  • agents include, but are not limited to, thrombolytic agents such as tissue plasminogen activator and streptokinase.
  • the second agent may be administered either as a separate dosage form or as part of a single dosage form with the compounds or compositions of this invention. Accordingly, a combined preparation for simultaneous, separate, or sequential use is provided by this invention.
  • Dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of a disease involving caspase activity and/or apoptosis.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a typical preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.
  • compositions of this invention comprise a combination of a compound of formula I and one or more additional therapeutic or prophylactic agents
  • both the compound and the additional agent should be present at dosage levels of between about 10 to 100%, and more preferably between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of active ingredients will also depend upon the particular compound and other therapeutic agent, if present, in the composition.
  • the invention provides a method of treating a mammal, having one of the aforementioned diseases, comprising the step of administering to said mammal a pharmaceutically acceptable composition described above.
  • a pharmaceutically acceptable composition described above.
  • the patient is also administered another therapeutic agent or caspase inhibitor, it may be delivered together with the compound of this invention in a single dosage form, or, as a separate dosage form.
  • the other caspase inhibitor or agent may be administered prior to, at the same time as, or following administration of a pharmaceutically acceptable composition comprising a compound of this invention.
  • the assays for caspase inhibition are based on the cleavage of a fluorogenic substrate by recombinant, purified human Caspases-1, -3, or -8.
  • the assays are run in essentially the same way as those reported by Garcia-Calvo et al. ( J. Biol. Chem. 273 (1998), 32608-32613), using a substrate specific for each enzyme.
  • the substrate for Caspase-1 is Acetyl-Tyr-Val-Ala-Asp-amino-4-methylcoumarin.
  • the substrate for Caspases -3 and -8 is Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin. Both substrates are known in the art.
  • the observed rate of enzyme inactivation at a particular inhibitor concentration, k obs is computed by direct fits of the data to the equation derived by Thornberry et al. (Biochemistry 33 (1994), 3943-3939) using a nonlinear least-squares analysis computer program (PRISM 2.0; GraphPad software). To obtain the second order rate constant, k inact , k obs values are plotted against their respective inhibitor concentrations and k inact values are subsequently calculated by computerized linear regression.
  • Human blood is freshly drawn from healthy donors and diluted 1:2 in PBS.
  • 50ml of prediluted test compound in RPMI medium and 10 ml LPS (5 ng/ml final concentration on the plate) are added (LPS, Serotype 0111:B4, Sigma L3012).
  • LPS lipoprotein
  • supernatants are collected and assayed for IL-1 ⁇ levels using the appropriate ELISA kit (R&D systems).
  • Table 2 below shows inhibition of IL-1 ⁇ secretion from human whole blood for selected compounds of this invention as determined individually by the above methods.
  • IC 50 ⁇ M
  • IC 50 1, 2, 3, 5, 7, 10, 11, 14, 17, & 29 ⁇ 0.5 4, 6, 8, 9, 12, 13, 15, 16, 18, 19, 20, 21, 0.5-5 22, 23, 28., 36, 38, & 39
  • Cortical neurons are dissociated from Wistar rat embryos (E17) by a modification of the procedure of Rogers et al. 1997, Brain Res. Bulletin, 44:131. Briefly, cerebral cortices are isolated aseptically from 15-20 Wistar rat embryos. A cell suspension is prepared by mincing the cerebral cortices and digesting them with papain. Cells are washed with ovomucoid enzyme inhibitor and DNaseI and plated onto Poly-D lysine coated plates in high glucose DMEM containing 10% heat-inactivated fetal calf serum, L-glutamine, penicillin and streptomycin. The yield of neurons is 10 ⁇ 7 per embryo and they are 80-90% viable as assessed by Trypan blue exclusion.
  • the neurons are cultured in complete medium at 37 ° C. in a normal atmosphere for 48 hours prior to the hypoxia experiments.
  • the normal cell medium is replaced by oxygen-depleted serum-free medium.
  • Cells are incubated in an atmosphere of 95% N2/5% CO 2 for various lengths of time.
  • the level of apoptosis is measured using a Cell Death Detection ELISA kit (Roche) which detects DNA fragmentation. Plates are read at 405 nm. Controls included cells cultured in aerobic conditions in serum-containing medium (+serum) and cells cultured in aerobic conditions in serum-deprived medium ( ⁇ serum).
  • Table 3 shows the results of the activity of selected compounds of this invention tested individually in the Hypoxia-induced apoptosis of rat cortical neurons.
  • TABLE 3 Activity in Hypoxia-induced Apoptosis Assay Compound Number IC 50 ( ⁇ M) 2, 5, 10, 11, 12, 13, 15, 17, 20, 22, 38, & ⁇ 1 39 1, 3, 4, 6, 7, 8, 9, 14, 16, 18, 19, 21, 24, 1-10 29, 30, 31, 34, 35, 36 & 37
  • Cellular apoptosis may be induced by the binding of Fas ligand (FasL) to its receptor, CD95 (Fas).
  • CD95 is one of a family of related receptors, known as death receptors, which can trigger apoptosis in cells via activation of the caspase enzyme cascade. The process is initiated by the binding of the adapter molecule FADD/MORT-1 to the cytoplasmic domain of the CD-95 receptor-ligand complex. Caspase-8 then binds FADD and becomes activated, initiating a cascade of events that involve the activation of downstream caspases and subsequent cellular apoptosis.
  • Apoptosis can also be induced in cells expressing CD95 e.g., the Jurkat E6.1 T cell lymphoma cell line, using an antibody, rather than FasL, to crosslink the cell surface CD95.
  • Anti-Fas-induced apoptosis is also triggered via the activation of caspase-8. This provides the basis of a cell based assay to screen compounds for inhibition of the caspase-8-mediated apoptotic pathway.
  • Jurkat E6.1 cells are cultured in complete medium consisting of RPMI-1640 (Sigma No)+10% foetal calf serum (Gibco BRL No.10099-141)+2mM L-glutamine (Sigma No. G-7513). The cells are harvested in log phase of growth. 100 ml of cells at 5-8 ⁇ 105 cells/ml are transferred to sterile 50 ml Falcon centrifuge tubes and centrifuged for 5 minutes at 100 ⁇ g at room temperature. The supernatant is removed and the combined cell pellets resuspended in 25 ml of complete medium. The cells are counted and the density adjusted to 2 ⁇ 106 cells/ml with complete medium.
  • test compound is dissolved in dimethyl sulfoxide (DMSO)(Sigma No. D-2650) to give a 100 mM stock solution. This is diluted to 400 ⁇ M in complete medium, then serially diluted in a 96-well plate prior to addition to the cell assay plate.
  • DMSO dimethyl sulfoxide
  • Apoptosis of the cells is measured by the quantitation of DNA fragmentation using a ‘Cell Death Detection Assay’ from Roche diagnostics, No. 1544 675. After incubation for 16-18 hrs the assay plates are centrifuged at 100 ⁇ g at room temperature for 5 minutes. 150 ⁇ l of the supernatant are removed and replaced by 150 ⁇ l of fresh complete medium. The cells are then harvested and 200 ⁇ l of the lysis buffer supplied in the assay kit are added to each well. The cells are triturated to ensure complete lysis and incubated for 30 minutes at 4° C. The plates are then centrifuged at 1900 ⁇ g for 10 minutes and the supernatants diluted 1:20 in the incubation buffer provided.
  • OD405 nm is measured 20 minutes after addition of the final substrate in a SPECTRAmax Plus plate reader (Molecular Devices). OD405 nm is plotted versus compound concentration and the IC50 values for the compounds are calculated using the curve-fitting program SOFTmax Pro (Molecular Devices) using the four parameter fit option.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
US10/855,699 2003-05-27 2004-05-27 Caspase inhibitors and uses thereof Abandoned US20040242494A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/855,699 US20040242494A1 (en) 2003-05-27 2004-05-27 Caspase inhibitors and uses thereof
US12/140,497 US7960415B2 (en) 2003-05-27 2008-06-17 Caspase inhibitors and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47362203P 2003-05-27 2003-05-27
US10/855,699 US20040242494A1 (en) 2003-05-27 2004-05-27 Caspase inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/140,497 Continuation US7960415B2 (en) 2003-05-27 2008-06-17 Caspase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
US20040242494A1 true US20040242494A1 (en) 2004-12-02

Family

ID=33490622

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/855,699 Abandoned US20040242494A1 (en) 2003-05-27 2004-05-27 Caspase inhibitors and uses thereof
US12/140,497 Expired - Fee Related US7960415B2 (en) 2003-05-27 2008-06-17 Caspase inhibitors and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/140,497 Expired - Fee Related US7960415B2 (en) 2003-05-27 2008-06-17 Caspase inhibitors and uses thereof

Country Status (19)

Country Link
US (2) US20040242494A1 (no)
EP (2) EP2412707A3 (no)
JP (4) JP4791365B2 (no)
KR (2) KR20060015626A (no)
CN (2) CN101775012A (no)
AR (1) AR044770A1 (no)
AU (1) AU2004243308B9 (no)
BR (1) BRPI0410669A (no)
CA (1) CA2526749A1 (no)
IL (1) IL172159A (no)
MX (1) MXPA05012837A (no)
NO (1) NO20056192L (no)
NZ (2) NZ544156A (no)
PE (1) PE20050159A1 (no)
RU (1) RU2372335C2 (no)
TW (2) TW201038534A (no)
UY (1) UY28333A1 (no)
WO (1) WO2004106304A2 (no)
ZA (1) ZA200509700B (no)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072850A1 (en) * 2002-06-28 2004-04-15 Ronald Knegtel Caspase inhibitors and uses thereof
US20060020016A1 (en) * 2004-03-12 2006-01-26 Tanoury Gerald J Processes and intermediates
US20060128696A1 (en) * 2004-05-15 2006-06-15 Annamaria Vezzani Treating seizures using ice inhibitors
US20060160862A1 (en) * 2004-11-24 2006-07-20 Jean-Damien Charrier Caspase inhibitors and uses thereof
US20060275215A1 (en) * 2003-11-26 2006-12-07 Duncan Hiscock Novel imaging agents
WO2006133147A2 (en) * 2005-06-08 2006-12-14 Novartis Ag Organic compounds
US20070155718A1 (en) * 2005-07-28 2007-07-05 Steven Durrant Caspase inhibitor prodrugs
US20090093416A1 (en) * 2003-05-27 2009-04-09 Guy Brenchley Caspase inhibitors and uses thereof
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US9352010B2 (en) 2011-07-22 2016-05-31 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
US9994613B2 (en) 2000-05-19 2018-06-12 Vertex Pharmaceuticals Incorporated Prodrug of an ICE inhibitor
US11091473B2 (en) 2018-05-29 2021-08-17 Acadia Pharmaceuticals Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
US11161826B2 (en) 2019-05-10 2021-11-02 Acadia Pharmaceuticals Inc. Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574791A (en) 2006-08-02 2011-12-22 Lg Life Sciences Ltd Caspase inhibitors based on pyridazinone scaffold
KR20080042290A (ko) * 2006-11-09 2008-05-15 주식회사 엘지생명과학 피리돈 구조를 포함하는 캐스파제 저해제
WO2010120880A1 (en) * 2009-04-14 2010-10-21 Vertex Pharmaceuticals Incorporated Treatment of liver diseases with a caspase inhibitor
CN104254526B (zh) * 2012-03-31 2017-06-20 乔治亚大学研究基金公司 针对结核病的新的抗分枝杆菌药物
EP2687511A1 (de) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinonderivate als Gewebetransglutaminaseinhibitoren
US9969283B2 (en) 2013-09-10 2018-05-15 General Electric Company Battery changing system and method
US10143267B1 (en) 2013-12-31 2018-12-04 Dynasty Footwear, Ltd. Shoe bottom surface having attached particles
EP3142649B1 (en) 2014-05-12 2019-07-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitor emricasan
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
BR112019005985A2 (pt) 2016-10-05 2019-06-25 Novartis Ag composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
EP3814327A1 (en) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728647A (en) * 1985-05-30 1988-03-01 Rhone-Poulenc Sante Amides derived from quinoline, and anxiolytic compositions containing them
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6525076B1 (en) * 1996-10-11 2003-02-25 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US20040048797A1 (en) * 2002-04-19 2004-03-11 Karen Miller Regulation of TNF-alpha
US20040072850A1 (en) * 2002-06-28 2004-04-15 Ronald Knegtel Caspase inhibitors and uses thereof
US20040192612A1 (en) * 2002-12-20 2004-09-30 Jean-Damien Charrier Caspase inhibitors and uses thereof
US20060160862A1 (en) * 2004-11-24 2006-07-20 Jean-Damien Charrier Caspase inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DE3261645D1 (en) 1981-02-03 1985-02-07 Airwick Ag Composition containing an abrasive substrate for the cleaning of hard surfaces
DD232699A1 (de) 1983-11-18 1986-02-05 Adw Ddr Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern
GB9207145D0 (en) * 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
GB9216272D0 (en) 1991-08-15 1992-09-09 Ici Plc Substituted heterocycles
JP3386125B2 (ja) 1992-02-21 2003-03-17 メルク エンド カンパニー インコーポレーテッド インターロイキン−１β変換酵素阻害剤としてのペプチジル誘導体
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
DK0752987T3 (da) 1994-03-31 2004-03-15 Vertex Pharma Pyrimidinylderivater som interleukininhibitorer
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
KR100400639B1 (ko) * 1995-04-27 2003-12-31 미쯔비시 웰 파마 가부시키가이샤 복소환식아미드화합물및그의의약용도
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
EP0946502B1 (en) 1996-10-11 2002-12-18 Warner-Lambert Company Sulfonamide interleukin-beta converting enzyme inhibitors
AU738341B2 (en) * 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
ATE363465T1 (de) * 1999-04-09 2007-06-15 Cytovia Inc Caspase inhibitoren und ihre verwendung
SI20744B (sl) 1999-05-07 2009-08-31 Texas Biotechnology Corp Derivati karboksilne kisline, ki inhibirajo vezavo integrinov na njihove receptorje
KR100767199B1 (ko) 1999-05-07 2007-10-17 엔싸이시브 파마슈티칼즈 인코퍼레이티드 인테그린이 이의 수용체에 결합하는 것을 억제하는프로판산 유도체
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
CA2409015A1 (en) 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2003024955A2 (en) * 2001-09-18 2003-03-27 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AU2002348533A1 (en) 2001-10-09 2003-05-26 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
ATE529430T1 (de) 2005-07-28 2011-11-15 Vertex Pharma Caspase-hemmer-propharmaka

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728647A (en) * 1985-05-30 1988-03-01 Rhone-Poulenc Sante Amides derived from quinoline, and anxiolytic compositions containing them
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6525076B1 (en) * 1996-10-11 2003-02-25 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US20040048797A1 (en) * 2002-04-19 2004-03-11 Karen Miller Regulation of TNF-alpha
US20040072850A1 (en) * 2002-06-28 2004-04-15 Ronald Knegtel Caspase inhibitors and uses thereof
US20040192612A1 (en) * 2002-12-20 2004-09-30 Jean-Damien Charrier Caspase inhibitors and uses thereof
US20060160862A1 (en) * 2004-11-24 2006-07-20 Jean-Damien Charrier Caspase inhibitors and uses thereof

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994613B2 (en) 2000-05-19 2018-06-12 Vertex Pharmaceuticals Incorporated Prodrug of an ICE inhibitor
US8129381B2 (en) 2002-06-28 2012-03-06 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20040072850A1 (en) * 2002-06-28 2004-04-15 Ronald Knegtel Caspase inhibitors and uses thereof
US7553852B2 (en) 2002-06-28 2009-06-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US8071618B2 (en) 2002-12-20 2011-12-06 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20100137359A1 (en) * 2002-12-20 2010-06-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US20090093416A1 (en) * 2003-05-27 2009-04-09 Guy Brenchley Caspase inhibitors and uses thereof
US7960415B2 (en) 2003-05-27 2011-06-14 Vertex Pharmaceutical Incoporated Caspase inhibitors and uses thereof
US20060275215A1 (en) * 2003-11-26 2006-12-07 Duncan Hiscock Novel imaging agents
US7834200B2 (en) 2004-03-12 2010-11-16 Vertex Pharmaceuticals Incorporated Processes and intermediates
US20090048429A1 (en) * 2004-03-12 2009-02-19 Tanoury Gerald J Processes and intermediates
US20060020016A1 (en) * 2004-03-12 2006-01-26 Tanoury Gerald J Processes and intermediates
US7381827B2 (en) 2004-03-12 2008-06-03 Vertex Pharmaceuticals Incorporated Processes and intermediates
US8293929B2 (en) 2004-03-12 2012-10-23 Vertex Pharmaceuticals Incorporated Processes and intermediates
US20110071298A1 (en) * 2004-03-12 2011-03-24 Vertex Pharmaceuticals Incorporated Processes and Intermediates
US20060128696A1 (en) * 2004-05-15 2006-06-15 Annamaria Vezzani Treating seizures using ice inhibitors
US20060160862A1 (en) * 2004-11-24 2006-07-20 Jean-Damien Charrier Caspase inhibitors and uses thereof
US8362043B2 (en) 2004-11-24 2013-01-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2006133147A3 (en) * 2005-06-08 2007-05-03 Novartis Ag Organic compounds
WO2006133147A2 (en) * 2005-06-08 2006-12-14 Novartis Ag Organic compounds
US7989441B2 (en) 2005-06-08 2011-08-02 Novartis Ag Organic compounds
US20090069294A1 (en) * 2005-06-08 2009-03-12 Zhuoliang Chen Organic Compounds
JP2008545780A (ja) * 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
US20110137037A1 (en) * 2005-07-28 2011-06-09 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US7879891B2 (en) * 2005-07-28 2011-02-01 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US8168798B2 (en) 2005-07-28 2012-05-01 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US20070155718A1 (en) * 2005-07-28 2007-07-05 Steven Durrant Caspase inhibitor prodrugs
US9352010B2 (en) 2011-07-22 2016-05-31 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
US11091473B2 (en) 2018-05-29 2021-08-17 Acadia Pharmaceuticals Inc. Compounds for pain treatment, compositions comprising same, and methods of using same
US11161826B2 (en) 2019-05-10 2021-11-02 Acadia Pharmaceuticals Inc. Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

Also Published As

Publication number Publication date
UY28333A1 (es) 2004-12-31
NZ544156A (en) 2009-05-31
RU2372335C2 (ru) 2009-11-10
PE20050159A1 (es) 2005-04-19
AR044770A1 (es) 2005-10-05
JP4791365B2 (ja) 2011-10-12
KR20110114735A (ko) 2011-10-19
EP1631549A2 (en) 2006-03-08
WO2004106304A3 (en) 2005-11-03
TWI344956B (en) 2011-07-11
US20090093416A1 (en) 2009-04-09
AU2004243308B2 (en) 2011-09-29
EP2412707A3 (en) 2012-06-13
AU2004243308A1 (en) 2004-12-09
NO20056192L (no) 2005-12-27
WO2004106304A2 (en) 2004-12-09
IL172159A0 (en) 2006-04-10
JP2012036206A (ja) 2012-02-23
EP2412707A2 (en) 2012-02-01
CA2526749A1 (en) 2004-12-09
NZ575857A (en) 2010-11-26
JP2007506803A (ja) 2007-03-22
ZA200509700B (en) 2007-03-28
JP2012021019A (ja) 2012-02-02
JP2007308501A (ja) 2007-11-29
CN1812972A (zh) 2006-08-02
TW201038534A (en) 2010-11-01
RU2005140657A (ru) 2006-06-10
AU2004243308B9 (en) 2012-02-09
CN101775012A (zh) 2010-07-14
IL172159A (en) 2012-03-29
TW200510317A (en) 2005-03-16
MXPA05012837A (es) 2006-02-13
US7960415B2 (en) 2011-06-14
KR20060015626A (ko) 2006-02-17
CN1812972B (zh) 2010-04-28
BRPI0410669A (pt) 2006-06-20

Similar Documents

Publication Publication Date Title
US7960415B2 (en) Caspase inhibitors and uses thereof
JP5055129B2 (ja) ３−［２−（３−アシルアミノ−２−オキソ−２ｈ−ピリジン−１−イル）−アセチルアミノ］−４−オキソ−ペンタン酸誘導体、およびカスパーゼ阻害剤としてのそれらの使用
JP2007506803A5 (no)
JP2008521809A5 (no)
US20020103227A1 (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
NZ519424A (en) Caspase inhibitors and uses thereof
JP2004509120A (ja) カスパーゼ阻害剤およびそれらの用途
WO2011153588A1 (en) Viral polymerase inhibitors
WO1995018097A1 (fr) Derive de l'acide anthranilique
NZ537807A (en) Caspase inhibitors and uses thereof
AU2003303345A1 (en) 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRENCHLEY, GUY;CHARRIER, JEAN-DAMIEN;DURRANT, STEVEN;AND OTHERS;REEL/FRAME:015401/0323;SIGNING DATES FROM 20040520 TO 20040524

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION